PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 4 filers reported holding PROGENICS PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $68,000 | -90.4% | 17,779 | -84.6% | 0.00% | -71.4% |
| Q2 2019 | $712,000 | +4.1% | 115,461 | -21.7% | 0.01% | 0.0% |
| Q1 2019 | $684,000 | -12.8% | 147,476 | -21.0% | 0.01% | -22.2% |
| Q4 2018 | $784,000 | -11.7% | 186,619 | +56.9% | 0.01% | -35.7% |
| Q1 2018 | $888,000 | +115.5% | 118,973 | +71.6% | 0.01% | +100.0% |
| Q4 2017 | $412,000 | +12.9% | 69,312 | +39.9% | 0.01% | 0.0% |
| Q3 2017 | $365,000 | -43.5% | 49,544 | -47.9% | 0.01% | -46.2% |
| Q2 2017 | $646,000 | +25.9% | 95,132 | +75.2% | 0.01% | -7.1% |
| Q1 2017 | $513,000 | +46.6% | 54,299 | +33.9% | 0.01% | 0.0% |
| Q4 2016 | $350,000 | +400.0% | 40,559 | +265.4% | 0.01% | +180.0% |
| Q3 2016 | $70,000 | -72.3% | 11,099 | -73.1% | 0.01% | -82.1% |
| Q4 2015 | $253,000 | +57.1% | 41,300 | +53.1% | 0.03% | -50.0% |
| Q1 2015 | $161,000 | – | 26,972 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 17,902,338 | $135,342,000 | 5.88% |
| TIGER MANAGEMENT L.L.C. | 1,288,454 | $9,741,000 | 1.91% |
| Phocas Financial Corp. | 1,047,181 | $7,917,000 | 0.69% |
| TUDOR INVESTMENT CORP ET AL | 2,370,503 | $17,921,000 | 0.62% |
| EAM Investors, LLC | 553,309 | $4,183,000 | 0.58% |
| Baker Brothers Advisors | 4,449,797 | $33,640,000 | 0.34% |
| TFS CAPITAL LLC | 463,740 | $3,506,000 | 0.33% |
| FEDERATED HERMES, INC. | 13,508,290 | $102,123,000 | 0.32% |
| Rotella Capital Management, Inc. | 36,473 | $276,000 | 0.24% |
| OXFORD ASSET MANAGEMENT LLP | 1,103,848 | $8,351,000 | 0.18% |